When you think about it's ironic how much we've advanced in the last 20 years on synthetic biology (next-gen sequencing, CRISPR, protein eng, etc) while we're still (mostly) using the same foundational tech from the 70s-80s pharma development in biomanufacturing. We're trying to run cutting-edge software on outdated hardware.
Hey Arye! I wonder if you have seen the latest report by Synonym and BCG about biomanufacturing capacity and cost reductions. I think you would enjoy it :) (I'm not affiliated with Synonym!)
Agreed on the need for scaled fit-for-purpose biomanufacturing facilities. Beyond larger fermenters, we’re also going to need integrated biorefineries that valorize co-products to make the unit economics work for commodity ingredients. Especially for precision fermentation where biomass far outweighs target product.
When you think about it's ironic how much we've advanced in the last 20 years on synthetic biology (next-gen sequencing, CRISPR, protein eng, etc) while we're still (mostly) using the same foundational tech from the 70s-80s pharma development in biomanufacturing. We're trying to run cutting-edge software on outdated hardware.
So well said!
Hey Arye! I wonder if you have seen the latest report by Synonym and BCG about biomanufacturing capacity and cost reductions. I think you would enjoy it :) (I'm not affiliated with Synonym!)
https://www.synonym.bio/synonym-bcg-report
Thanks Eshan, yes! It's great background illustrating the challenge and opportunity here.
Agreed on the need for scaled fit-for-purpose biomanufacturing facilities. Beyond larger fermenters, we’re also going to need integrated biorefineries that valorize co-products to make the unit economics work for commodity ingredients. Especially for precision fermentation where biomass far outweighs target product.
Also – the post picture is hilarious 😂